You are here: Industry Insights > AbbVie

News List

Spooked AbbVie investors are selling off shares—but do they need to be? fiercepharma
July 23, 2018
AbbVie investors are running for the exits after comments on biosimilars from the FDA head, proposed rebate rule changes from the Trump administration and an ominous short-seller tweet. But they don’t need to be, industry watchers say.
AbbVie Announces HUMIRA Patent License with Mylan biospectrumasia
July 19, 2018
Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA
Biogen, Samsung Bioepis and Abbvie settle patent dispute pharmatimes
July 18, 2018
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial pharmafile
July 17, 2018
AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma.
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial pharmatimes
July 16, 2018
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial pharmatimes
July 13, 2018
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Judge strikes $140M AndroGel verdict after AbbVie appeal fiercepharma
July 09, 2018
Right on the heels of a legal setback relating to AndroGel antitrust claims, AbbVie has scored a reversal of a $140 million verdict in the case of a plaintiff who argued the company's testosterone drug caused his heart attack.
AbbVie dumps Galapagos’ cystic fibrosis combo on back of underwhelming data drop fiercebiotech
July 09, 2018
AbbVie has dumped one of Galapagos’ cystic fibrosis regimens after getting a look at underwhelming clinical data on a component of the triple combination.
AbbVie ordered to pay $448m over generic delays pharmafile
July 06, 2018
he ruling made in Philadelphia by US District Judge Harvey Bartle acted to conclude an anti-trust lawsuit first filed in 2014 by the Federal Trade Commission against AbbVie and its partner Besins Healthcare.
AbbVie, Calico extend age-related diseases collaboration pharmatimes
July 04, 2018
AbbVie and Calico have expanded their agreement to develop treatments for age-related diseases for a further three years.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page